145783-14-8

Basic information

• Product Name: 4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE
• Synonyms: 4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE;PyriMidine, 4,6-dichloro-5-nitro-2-(propylthio)-;4,6-dichloro-5-nitro-2-(propylsulfanyl)pyriMidine;4,6-dichloro-5-nitro-2-(propylsulfanyl)pyriMidine 4,6-dichloro-5-nitro-2-(propylsulfanyl)pyriMidine;4,6-Dichloro-5-nitro-2-(propythio)pyrimidine;4,6-Dichloro-5-nitro-2-propylthiopyridine;4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDI;EOS-61674
• CAS NO: 145783-14-8
• Molecular Formula: C₇H₇Cl₂N₃O₂S
• Molecular Weight: 268.12
• EINECS: 1312995-182-4
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series;Intermediate of Ticagrelor
• Mol File: 145783-14-8.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 377.79 °C at 760 mmHg
• Flash Point: 182.281 °C
• Appearance: Yellow power
• Density: 1.547 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Sparingly), DMSO (Sparingly), Ethyl Acetate (Slightly)
• PKA: -8.48±0.50(Predicted)
• Stability: Unstable in DMSO Solution
• CAS DataBase Reference: 4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE(145783-14-8)
• EPA Substance Registry System: 4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE(145783-14-8)

Safety Data

• Hazardous Substances Data: 145783-14-8(Hazardous Substances Data)

Usage

Description

4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE is an organic compound with the molecular formula C8H7Cl2N3O2S. It is characterized by the presence of two chlorine atoms at the 4 and 6 positions, a nitro group at the 5 position, and a propylthio group at the 2 position. 4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE serves as a key intermediate in the synthesis of various biologically active molecules.

Uses

Used in Pharmaceutical Industry:
4,6-DICHLORO-5-NITRO-2-PROPYLTHIOPYRIMIDINE is used as a reactant in the synthesis of carba-nucleosides, which are potent antagonists of the ADP purinergic receptor P2Y12 on human platelets. These antagonists play a crucial role in the prevention of blood clot formation, making them valuable in the treatment and management of conditions such as atherosclerosis, acute coronary syndrome, and stroke.
The compound's unique structural features allow it to be a versatile building block in the development of new therapeutic agents targeting various diseases. Its application in the pharmaceutical industry is primarily focused on the synthesis of novel compounds with potential therapeutic benefits.

InChI:InChI=1/C7H7Cl2N3O2S/c1-2-3-15-7-10-5(8)4(12(13)14)6(9)11-7/h2-3H2,1H3

Upstream product

• 145783-13-7 4,6-dihydroxy-5-nitro-2-(propylthio)pyrimidine 
• 91-66-7 N,N-diethylaniline 
• 145783-13-7 6-Hydroxy-5-nitro-2-(propylthio)-4(1H)-pyrimidinone 
• 121-69-7 N,N-dimethyl-aniline 
• 145783-13-7 6-hydroxy-5-nitro-2-(propylthio)-4(3H)-pyrimidinone 
• 145783-12-6 4,6-dihydroxy-2-(propylsulfanyl)pyrimidine 

Downstream Products

• 145783-15-9 4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine 
• 220241-59-8 (3aR,4S,6R,6aS)-6-((6-chloro-5-nitro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 639855-38-2 N-(4-chlorophenyl)-6-morpholin-4-yl-5-nitro-2-(propylthio)pyrimidin-4-amine 
• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 376608-74-1 2-[((3aR,4S,6R,6aS)-6-[[5-amino-6-chloro-2-(propylsulfanyl)-4-pyrimidinyl]amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy]-1-ethanol 
• 376608-75-2 2-({(3aR,4S,6R,6aS)-6-[7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl]-2,2-dimethyltetrahydro-3aH-cyclopentadiene[d][1,3]dioxolene-4-yl}oxy)ethanol 
• 274693-27-5 ticagrelor 
• 1383715-59-0 2-[[(3aR,4S,6R,6aS)-6-[[4-[N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino]-2-(propylthio)-5-nitropyrimidin-6-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy] ethanol 
• 1383715-60-3 2-[[(3aR,4S,6R,6aS)-6-[[4-[N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino]-2-(propylthio)-5-aminopyrimidin-6-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol 
• 1383715-61-4 tert-butyl N-[3-[(3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]carbamate 
• 1383715-62-5 2-({(3aR,4S,6R,6aS)-6-[7-{[[N-(IR,2S)-2-(3,4-difluorophenyl)-cyclopropan-1-yl]-N-benzyl]amino}-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}oxy)ethanol 
• 1383715-63-6 C₃₀H₃₄F₂N₆O₄S 
• 1383715-64-7 2-({(3aR,45,6R,6aS)-6-[7-{[[N-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino}-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}oxy)-O-tertbutoxycarbonylethanol 
• 1383715-58-9 tert-butyl (6-chloro-5-nitro-2-(propylthio)pyrimidin-4-yl)((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)carbamate 

Relevant articles and documents

Pyrimido triazole compound and medical application thereof (by machine translation)

The present invention relates to a compound of general (I) or a hydrate thereof or a pharmaceutically acceptable salt, thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same or a pharmaceutically acceptable salt thereof, and use, of the compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament . The medicament is for anti-platelet aggregation and treatment of related diseases such as antithrombotic . (by machine translation)

Method for preparing 4,6-dichloro-5-nitro-2-(propylmercapto)-pyrimidine

The invention discloses a method for preparing 4,6-dichloro-5-nitro-2-(propylmercapto)-pyrimidine. The method comprises the following steps: dissolving 6-hydroxy-5-nitro-2-(propylmercapto)-4-(3H)-pyrimidone into toluene, performing cooling, slowly dropping pyrophosphoryl chloride, performing heating, adding a catalyst, performing a reaction for 10-40 hours, performing cooling after the reaction is ended, pouring the reaction system into ice water, performing stirring and layering, adding neutral silica gel of 60-120 meshes into the upper toluene layer, performing stirring, performing filtration, and performing rotary evaporation on the filtrate to recycle the toluene so as to obtain the oily 4,6-dichloro-5-nitro-2-(propylmercapto)-pyrimidine. The method is mild in reaction condition, high in reaction yield and small in environment pollution.

For the improvement of the [...] intermediates preparation method

The invention relates to an improved preparation method for the intermediate 4, 6-dihalogen-2-(propythio)pyrimidine-5-amine used for preparing the anticoagulation drug ticagrelor, and application of the intermediate in preparation of ticagrelor. By use of a phase transfer reagent, the method reduces the halogenating reagent consumption and emission and treatment of toxic substances. Also, the obtained product has high yield and good purity. Thus, the method is a greener and more economical preparation method more suitable for industrial application.